Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants

PLoS Medicine

Volumn 3, Issue 7, 2006, Pages 1071-1079

  Ter Meulen, Jan ^a   Van Den Brink, Edward N ^a   Poon, Leo L M ^b   Marissen, Wilfred E ^a   Leung, Cynthia S W ^b   Cox, Freek ^a   Cheung, Chung Y ^b   Bakker, Arjen Q ^a   Bogaards, Johannes A ^a   Van Deventer, Els ^a   Preiser, Wolfgang ^c   Doerr, Hans Wilhelm ^c   Chow, Vincent T ^d   De Kruif, John ^a   Peiris, Joseph S M ^b   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GOETHE UNIVERSITY   (Germany)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CR3014; MONOCLONAL ANTIBODY CR3022; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ANTISERUM; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MEMBRANE PROTEIN; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE REDUCTION; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG DISEASE; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; RECEPTOR BINDING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS SHEDDING; VIRUS STRAIN; AMINO ACID SUBSTITUTION; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGENIC VARIATION; BINDING SITE; CELL CULTURE; CERCOPITHECUS; CHEMISTRY; DOSE RESPONSE; DRUG POTENTIATION; EPIDEMIC; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; MISSENSE MUTATION; MOLECULAR GENETICS; NANDINIIDAE; PASSIVE IMMUNIZATION; PHYSIOLOGY; POINT MUTATION; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS; SURFACE PLASMON RESONANCE; VERO CELL; VIROLOGY; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENIC VARIATION; ANTIGENS, VIRAL; BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; EPITOPES; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NANDINIIDAE; NEUTRALIZATION TESTS; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURFACE PLASMON RESONANCE; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 33746424849     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030237     Document Type: Article

References (52)

1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
2. Peiris JS, Guan Y, Yuen KY (2004). Severe acute respiratory syndrome. Nat Med 10: S88-S97.
3. Donnelly CA, Fisher MC, Frazer C, Ghani AC, Riley S, et al. (2004). Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 4: 672-683.
4. Gupta AG, Moyer CA, Stern DT (2005) The economic impact of quarantine: SARS in Toronto as a case study. J Infect 50: 386-393.
5. The Conference Board of Canada (2003) The economic impact of SARS. Available: http://www.conferenceboard.ca/documents.asp?rnext=539. Accessed 7 February 2006.
6. Liang G, Chen Q, Xu J, Liu Y, Lim W, et al. (2004) Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis 10: 1774-1781.
7. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, et al. (2005) Cross-evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 102: 2430-2435.
8. Chinese SARS Molecular Epidemiology Consortium (2004) Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303: 1666-1669.
9. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
10. Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi H-W, et al. (2005). Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 102: 14040-14045.
11. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, et al. (2004) Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101: 6641-6646.
12. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, et al. (2004) Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 101: 9804-9809.
13. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, et al. (2004) Mucosal immunization of African green monkey (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363: 2122-2127.
14. Burnouf T, Radosevich M (2003) Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 9: 309-310.
15. Li G, Chen X, Xu A (2003) Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 349: 508-509.
16. Wong S, Dai D, Wu AK, Sung JJ ( 2003) Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 9: 199-201.
17. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, et al. (2005) Development and characterization of a severe acute respiratory-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Inf Dis 191: 507-514.
18. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, et al. (2004) Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78: 3572-3577.
19. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, et al. (2005) Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 79: 5900-5906.
20. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10: 871-875.
21. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, et al. (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363: 2139-2141.
22. van den Brink EN, ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, et al. (2005) Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 79: 1635-1644.
23. Pavia AT, Nielsen L, Armington L, Thurman DJ, Tierney E, et al. (1990) A community-wide outbreak of hepatitis A in a religious community: Impact of mass administration of immune globulin. Am J Epidemiol 131: 1085-1093.
24. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (1996) Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention. MMWR Recomm Rep 45: 1-36.
25. Corapi WV, Olsen CW, Scott FW (1992) Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 66: 6695-6705.
26. Cheung CY, Poon LL, Ng IH, Luk W, Sia SF, et al. (2005) Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: Possible relevance to pathogenesis. J Virol 79: 7819-7826.
27. de Kruif J, Boel E, Logtenberg T (1995) Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol 248: 97-105.
28. Kramer RA,, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, et al. (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35: 2131-2145.
29. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
30. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, et al. (2001) Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75: 12198-12208.
31. Poon LL, Chan KH, Wong OK, Cheung TK, Ng I, et al. (2004) Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem 50: 67-72.
32. La Montagne JR, Taylor SL, Turnbull RJ, and the SARS research working group co-chairs (2004) Severe acute respiratory syndrome: Developing a research response. J Infect Dis 189: 642-647.
33. Tsang OT, Chau TN, Choi KW, Tso EY, Lim W, et al. (2003) Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 9: 1381-1387.
34. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, et al. (2005) Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 102: 797-801.
35. Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279: 3197-3201.
36. He Y, Zhu Q, Liu S, Zhou Y, Yang B, et al. (2005) Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines. Virology 334: 74-82.
37. Wang S, Chou TW, Sakhatskyy PV, Huang S, Lawrence JM, et al. (2005) Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 79: 1906-1910.
38. He Y, Hu L, Siddiqui P, Zhou Y, Jiang S (2005) Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174: 4908-4915.
39. Zhang Z, Xie YW, Hong J, Zhang X, Kwok SY, et al. (2005) Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion 45: 1160-1164.
40. Meissner HC, Long SS (2003) Revised indications for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infection. Pediatrics 112: 1447-1441.
41. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, et al. (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24: 1634-1643.
42. Qu X, Hao P, Song XJ, Jiang SM, Liu YX, et al. (2005) Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem 280: 29588-29595.
43. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79: 9062-9068.
44. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, et al. (1994) Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 68: 4001-4008.
45. Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, et al. (1998) Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immuoglobulins. J Virol 72: 3235-3240.
46. Klonisch T, Panayotou G, Edwards P, Jackson AM, Berger P, et al. (1996) Enhancement in antigen binding by a combination of synergy and antibody capture. Immunology 89: 165-171.
47. Xu D, Zhang Z, Wang FS (2004) SARS-associated coronavirus quasispecies in individual patients. N Engl J Med 350: 1366-1377.
48. Liu J, Lim SL, Ruan Y, Ling AE, Ng LFP, et al. (2005) SARS transmission pattern in Singapore reassessed by viral sequence variation analysis. PLoS Med 2: 162-168.
49. Poon LLM, Leung CSW, Yuen KY, Guan Y, Peiris JSM (2005) Recurrent mutations associated with isolation and passage of SARS coronavirus in cells from non-human primates. J Med Virol 9999: 1-6.
50. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achebach JE, et al. (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101: 15748-15753.
51. Klepfer S, Reed AP, Martinez M, Bhogal B, Jones E, et al. (1995) Cloning and expression of FECV spike gene in vaccinia virus. Immunization with FECV S causes early death after FIPV challenge. Adv Exp Med Biol 380: 235-241.
52. Takada A, Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. Rev Med Virol 13: 387-398.